Pfenex Inc.announced the IND for Px563L, Pfenex's recombinant anthrax vaccine, has been filed and is now open and that this programme has received additional funding provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).

"We are extremely pleased to have the IND now active for our recombinant anthrax vaccine, Px563L.  This represents a significant milestone in our company's partnership with BARDA as we continue to advance this important programme," stated Bertrand C. Liang, chief executive officer of Pfenex. "We appreciate the additional funding support provided by BARDA for this programme and look forward to continuing this successful collaboration."